On Thursday 31 October, the European Commission imposed a fine of €462.6 million on the pharmaceutical giant Teva for abusing its dominant position to delay competition for its medicine, Copaxone, used to treat multiple sclerosis (see EUROPE B13039A26).
The investigation by the European Union institution revealed that Teva had abused its dominant position on the markets for glatiramer acetate, the active pharmaceutical ingredient on which the company held a basic patent until 2015, in...